Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
Clinical trial NCT02964507 · TERMINATED
Trial details
- NCT number
- NCT02964507
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-26
- Primary completion
- 2020-09-29
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.